Efficacy Of Oral Azithromycin Research Articles

Efficacy of Oral Azithromycin in Treatment of Uncomplicated Enteric Fever in Children

Background: Enteric fever also known as (typhoid or paratyphoid fever) is a common systemic infection with increased incidence of morbidity and mortality with salmonella typhi and paratyphi. Azithromycin has shown better outcomes in children with uncomplicated disease. Objective: To determine the efficacy of Azithromycin in treatment of uncomplicated enteric fever in children. Study Design: Descriptive case series study Place and Duration of Study: Department of Pediatrics, Sir Ganga Ram Hospital Lahore, Pakistan from 21st August 2015 to 20th February 2016. Methodology: One hundred and sixty five cases were included. Patients received capsule/suspension of Azithromycin (10 mg/kg/day) OD for 7 days. Treatment was labelled as effective if both clinical and microbiological cure were observed. Results: Patients ranged between 2-12 years of age. Mean age of the patients was 6.45±2.39 year. There were 85 males (51.5%) and 80 females (48.5%) in this study. Mean duration of fever was 6.97±1.37 days. Clinical cure, microbiological cure and efficacy was 93.9%. Conclusion: Azithromycin to be effective and safe in treatment of enteric fever. We observed high cure rate of 93.9% without any serious side effects leading to the conclusion that azithromycin is an effective oral agent for treatment for enteric fever. Keywords: Enteric Fever, Azithromycin, Salmonella Typhi/Paratyphi

Oral Azithromycin Pulse Therapy and Daily Topical Adapalene in the Treatment of Acne Vulgaris: An Open Randomized Noncomparative Study

The safety and efficacy of oral azithromycin and topical adapalene are well documented. In this study, concomitant use of oral azithromycin pulse therapy and daily topical adapalene in the treatment of acne vulgaris is assessed. A total of 37 patients fulfilled the inclusion criteria were enrolled. Azithromycin, 500 mg orally once daily first 3 days of 10 days' cycle for 9 cycle & topical Adapalene (0.5%) at night. Patients evaluated at 4 weeks' interval by using Michaelsson acne severity index. The overall assessment was made by percent reduction of acne lesions and severity score. At the end of 12 weeks' treatment 99.8% of comedones, 98.7% papular lesion, 94.3% pustular lesion and 88.8% infiltrated lesion were cleared. Only 2.9% cystic lesion responded to the regimens. Percent reduction of Michaelsson acne severity index was 87%, which was statistically highly significant. Overall assessment revealed acne lesion cleared in 22% cases, excellent improvement observed in 65% and 13% showed good response. Adverse effect was minimal. So, azithromycin pulse therapy and topical adapalene is indeed effective and safe in the treatment of acne vulgaris.Medicine Today 2016 Vol.28(2): 52-56

The efficacy of oral azithromycin in clearing ocular chlamydia: Mathematical modeling from a community-randomized trachoma trial

Mass oral azithromycin distributions have dramatically reduced the prevalence of the ocular strains of chlamydia that cause trachoma. Assessing efficacy of the antibiotic in an individual is important in planning trachoma elimination. However, the efficacy is difficult to estimate, because post-treatment laboratory testing may be complicated by nonviable organisms or reinfection. Here, we monitored ocular chlamydial infection twice a year in pre-school children in 32 communities as part of a cluster-randomized clinical trial in Tanzania (prevalence in children was lowered from 22.0% to 4.7% after 3-year of annual treatment). We used a mathematical transmission model to estimate the prevalence of infection immediately after treatment, and found the effective field efficacy of antibiotic in an individual to be 67.6% (95% CI: 56.5–75.1%) in this setting. Sensitivity analyses suggested that these results were not dependent on specific assumptions about the duration of infection. We found no evidence of decreased efficacy during the course of the trial. We estimated an 89% chance of elimination after 10 years of annual treatment with 95% coverage.

Efficacy and Safety of Azithromycin vs Levofloxacin in the Outpatient Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis

To compare the safety and efficacy of oral azithromycin and levofloxacin in the treatment of outpatients with acute bacterial exacerbations of chronic bronchitis (ABECB). Randomized, double-blinded, double-dummy, multicenter trial with 1:1 treatment allocation. Outpatient treatment setting. Two hundred thirty-five male or female outpatients between the ages of 35 and 75 years who had received a clinical diagnosis of ABECB. Blinded treatment with either oral azithromycin, 500 mg on day 1 and 250 mg per day for days 2 to 5, or, oral levofloxacin, 500 mg q24h for 7 days. Both treatments were well-tolerated, with the majority of adverse events being GI in nature. Favorable clinical outcomes in clinically evaluable patients were demonstrated in 89% of patients receiving azithromycin and in 92% of patients receiving levofloxacin by day 4 of therapy. At day 24, the posttherapy visit, favorable responses were approximately 82% and 86%, respectively, for patients in the two treatment groups. The bacterial eradication rates of respiratory pathogens were 96% for azithromycin and 85% for levofloxacin. Despite increasing concerns over macrolide resistance and a higher incidence of Gram-negative pathogens, a standard 5-day course of oral azithromycin was clinically and bacteriologically equivalent to a 7-day course of oral levofloxacin in the treatment of patients with ABECB.